Ullmann N-Arylation/2-Amidation Cascade by Self-Relay Copper Catalysis: One-pot Synthesis of Indolo[1,2-*a*]quinazolinones Supporting Information

Takumi Abe*, Yuka Takahashi, Yuki Matsubara, and Koji Yamada Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-tobetsu, Hokkaido 0610293, Japan E-mail: abe-t@hoku-iryo-u.ac.jp

Contents	
1.	General Methods
	2
2.	Synthesis of 2a-l 2-4
3.	Synthesis of 3a , 4a , 5 5
4.	Synthesis of 3b-3o , 4b
5.	Synthesis of 3p 10
6.	References 10
7.	Copies of ¹ H, ¹³ C-NMR spectra 11–44

EXPERIMENTAL

1. General Methods.

Melting points were recorded with a Yamato MP21 and are uncorrected. High-resolution MS spectra were recorded with a Micromass AutoSpec 3100 and a JEOL JMS-T100LP mass spectrometers. IR spectra were measured with a Shimadzu IRAffinity-1 spectrometer. The NMR experiments were performed with a JEOL JNM-ECA500 (500 MHz) spectrometer, and chemical shifts are expressed in ppm (δ) with TMS as an internal reference. Column chromatography, Flash column chromatography and Medium Pressure Liquid Chromatography (MPLC) were performed on silica gel (Silica Gel 60N, Kanto Chemical Co., Ltd.). Methyl 5-methoxyindole-3-carboxylate (**1b**), Methyl 5-chloroindole-3-carboxylate (**1c**), Methyl 5-bromoindole-3-carboxylate (**1c**), and Methyl 5-nitroindole-3-carboxylate (**1d**) were prepared according to the reported procedures¹⁻².

2. Synthesis of 2-Halobenzamides 2a-j:

General procedure A for Preparation of Substrate 2a-j:

DMF (0.1 mL) was added to a mixture of 2-halobenzoic acids (50 mmol) in thionyl chloride (20 mL) at room temperature and reflux. After 3 h, thionyl chloride was removed in vacuo and to give the crude acid chloride. To a solution of the crude acid chloride in THF (80 mL), amine (100 mmol) was added dropwise at 0 °C and the mixture was stirred at room temperature. After 16 h, the mixture was added to 10% HCl solution at 0 °C, extracted with AcOEt (300 mL), washed with brine, and dried over MgSO₄. The solvent was removed, and the residue was purified by recrystallization (EtOH) to give 2-halobenzamides **2a-l**.

2-Bromobenzamide (2a).

Following the general procedure A from 2-bromobenzoic acid, **2a** (8.62 g, 86%) was obtained as white solids.

8.62 g, 86%. White solids. Mp: 165-167 °C (EtOH). IR (CHCl₃): 3304, 1668 cm⁻¹. ¹H-NMR (CDCl₃) δ : 6.14 (br s, 2H), 7.29 (td, J = 1.7, 8.0 Hz, 1H), 7.37 (td, J = 1.2, 8.0 Hz, 1H), 7.60 (dd, J = 1.2, 7.7 Hz, 1H), 7.63 (dd, J = 1.8, 7.5 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 119.3, 127.7, 130.0, 131.8, 133.7, 136.7, 169.4. HR-ESI-MS *m/z*: Calcd for C₇H₇BrNO [(M+H)⁺]: 199.9711, 201.9691. Found 199.9715, 201.9690.

NH₂

 NH_2

2-Chlorobenzamide (2b).

Following the general procedure A from 2-chlorobenzoic acid, **2b** (6.09 g, 78%) was obtained as white solids. 6.09 g, 78%. White solids. Mp: 139-141 °C (EtOH). IR (CHCl₃): 3400, 1665 cm⁻¹. ¹H-NMR (DMSO d_6) δ : 7.31-7.35 (m, 1H), 7.37-7.41 (m, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.55 (br s, 1H), 7.83 (br s, 1H). ¹³C-NMR (DMSO- d_6) δ : 127.5, 129.2, 130.1, 131.1, 137.7, 168.7. HR-ESI-MS *m/z*: Calcd for C_7H_7CINO [(M+H)⁺]: 156.0216, 158.0187. Found 156.0216, 158.0192.

2-Iodobenzamide (2c).

Following the general procedure A from 2-iodobenzoic acid, **2c** (8.92 g, 72%) was obtained as white solids. 8.92 g, 72%. White solids. Mp: 185-187 °C (EtOH). IR (CHCl₃): 3304, 1670 cm⁻¹. ¹H-NMR (DMSO- d_6) δ : 7.11 (td, J = 1.2, 7.5 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.48 (br s, 1H), 7.79 (br s, 1H), 7.83 (d, J = 8.1 Hz, 1H). ¹³C-NMR(DMSO- d_6) δ : 93.7, 128.3, 128.5, 131.1, 139.7, 143.7, 171.2. HR-ESI-MS *m/z*: Calcd for C₇H₆INNaO [(M+Na)⁺]: 269.9392. Found 269.9395.

2-Bromo-N-methylbenzamide (2d).

Following the general procedure A from 2-bromobenzoic acid, **2d** (7.59 g, 71%) was obtained as white solids.

7.59 g, 71%. White solids. Mp: 132-134 °C (EtOH). IR (CHCl₃): 3324, 1716, 1663 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.00 (d, J = 5.2 Hz, 3H), 6.04 (br s, 1H), 7.25 (td, J = 1.8, 7.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.50 (dd, J = 1.1, 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 26.8, 119.3, 127.6, 129.7, 131.3, 133.4, 137.9, 168.4. HR-ESI-MS *m*/*z*: Calcd for C₈H₈BrNNaO [(M+Na)⁺]: 235.9687, 237.9666. Found 235.9682, 237.9670.

2-Bromo-N-(tert-buthyl)benzamide (2e).

Following the general procedure A from 2-bromobenzoic acid, **2e** (6.04 g, 47%) was obtained as white solids.

6.04 g, 47%. White solids. Mp: 97-100 °C (EtOH). IR (CHCl₃): 3321, 1667 cm⁻¹. ¹H-NMR (DMSO d_6) δ : 1.32 (s, 9H), 7.26-7.29 (m, 2H), 7.36 (t, J = 6.9 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.97 (br s,

1H). ¹³C-NMR (DMSO- d_6) & 28.9, 51.4, 119.5, 127.9, 129.1, 130.8, 132.9, 140.7, 167.4 (two sp² signals were not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₁₁H₁₄BrNNaO [(M+Na) ⁺]: 278.0156, 280.0136. Found 278.0161, 280.0139.

N-Benzyl-2-bromobenzamide (2f).

Following the general procedure A from 2-bromobenzoic acid, **2f** (11.94 g, 82%) was obtained as white solids.

11.94 g, 82%. White solids. Mp: 115-117 °C (EtOH). IR (CHCl₃): 3319, 3305, 1663 cm⁻¹. ¹H-NMR (CDCl₃) δ : 4.65 (d, *J* = 5.7 Hz, 2H), 6.28 (br s, 1H), 7.24-7.31 (m, 2H), 7.33-7.39 (m, 5H), 7.55 (d, *J* = 7.5 Hz, 1H), 7.57 (d, *J* = 8.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 44.3, 119.4, 127.7, 127.8, 128.1, 128.9, 129.7, 131.4, 133.5, 137.7, 137.8, 167.6 (two sp² signals were not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₁₄H₁₂BrNNaO [(M+Na)⁺]: 312.0000, 313.9979. Found 312.0000, 313.9982.

2-Bromo-N-phenylbenzamide (2g).

Following the general procedure A from 2-bromobenzoic acid, **2g** (8.00 g, 58%) was obtained as white solids.

8.00 g, 58%. White solids. Mp: 125-126 °C (EtOH). IR (CHCl₃): 3304, 1678, 1600 cm⁻¹. ¹H-NMR (CDCl₃) δ : 7.16 (t, *J* = 7.5 Hz, 1H), 7.28 (t, *J* = 8.0 Hz, 1H), 7.35 (t, *J* = 8.0 Hz, 3H), 7.56-7.63 (m,



NH₂

Br HN

Me



4H), 7.91 (br s, 1H). ¹³C-NMR (CDCl₃) δ: 119.4, 120.2, 124.9, 127.8, 129.2, 129.8, 131.7, 133.6, 137.7, 137.9, 165.8 (two sp² signals were not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₁₃H₁₀BrNNaO [(M+Na) ⁺]: 297.9843, 299.9823. Found 297.9847, 299.9824.

N-Benzyl-2-bromo-5-methylbenzamide (2h).

Following the general procedure A from 2-bromo-5-methylbenzoic acid, **2h** (10.37 g, 68%) was obtained as white solids.

10.37 g, 68%. White solids. Mp: 130-132 °C (EtOH). IR (CHCl₃): 3323, 1663 cm⁻¹. ¹H-NMR (DMSO- d_6) δ : 2.26 (s, 3H), 4.40 (d, J = 5.8 Hz, 2H), 7.14 (dd, J = 2.3, 8.6 Hz, 1H), 7.21-7.24 (m, 2H), 7.29-7.35 (m, 4H), 7.48 (d, J = 8.0 Hz, 1H), 8.89 (t, J = 5.7 Hz, 1H). ¹³C-NMR (DMSO- d_6) δ : 20.8, 42.9, 116.1, 127.3, 127.8, 128.8, 129.8, 132.0, 133.0, 137.7, 139.4, 139.7, 167.9 (two sp² signals were not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₁₅H₁₅BrNNO [(M+H)⁺]: 304.0337, 306.0317. Found 304.0336, 306.0323.

N-Benzyl-2-bromo-5-chlorobenzamide (2i).

Following the general procedure A from 2-bromo-5-chlorobenzoic acid, **2i** (11.69 g, 72%) was obtained as white solids.

11.69 g, 72%. White solids. Mp: 164-165 °C (EtOH). IR (CHCl₃): 3306, 1667 cm⁻¹. ¹H-NMR c¹ 2ⁱ (DMSO-*d*₆) δ : 4.41 (d, *J* = 5.7 Hz, 1H), 7.23 (t, *J* = 6.9 Hz, 1H), 7.29-7.35 (m, 4H), 7.41 (dd, *J* = 2.3, 8.0 Hz, 1H), 7.48 (d, *J* = 2.3 Hz, 1H), 7.65 (d, *J* = 8.6 Hz, 1H), 9.02 (t, *J* = 5.7 Hz, 1H). ¹³C-NMR (DMSO-*d*₆) δ : 43.1, 118.0, 127.4, 127.9, 128.9, 129.0, 131.2, 132.9, 135.0, 139.3, 141.1, 166.4 (two sp² signals were not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₁₄H₁₁BrClNNaO [(M+Na) ⁺]: 345.9610, 347.9590. Found 345.9607, 347.9587.

N-Benzyl-2,5-dibromobenzamide (2j).

Following the general procedure A from 2,5-dibromobenzoic acid, **2j** (11.33 g, 61%) was obtained as white solids.



11.33 g, 61%. White solids. Mp: 176-178 °C (EtOH). IR (CHCl₃): 3433, 1668 cm⁻¹. ¹H-NMR ^{**b**r ²j} (DMSO-*d*₆) δ : 4.40 (d, *J* = 5.8 Hz, 1H), 7.22 (t, *J* = 6.3 Hz, 1H), 7.29-7.34 (m, 4H), 7.53 (dd, *J* = 2.9, 8.6 Hz, 1H), 7.58 (d, *J* = 4.0 Hz, 1H), 7.59 (d, *J* = 2.3 Hz, 1H), 9.01 (t, *J* = 5.8 Hz, 1H). ¹³C-NMR (DMSO-*d*₆) δ : 51.5, 87.9, 113.1, 115.6, 117.7, 121.2, 122.7, 124.3, 125.2, 127.0, 130.0, 131.1, 135.3, 138.7, 142.3, 158.0, 166.2 (two sp² signals were not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₁₄H₁₁Br₂NNaO [(M+Na) ⁺]: 389.9105, 391.9085, 393.9064. Found 389.9111, 391.9076, 393.9064.

3. Synthesis of 3a, 4a, 5:

General procedure B for Table 1:

Base (2 mmol) was added to a mixture of indole (1 mmol), 2a (300 mg, 1.5 mmol), Cu-catalyst (0.1 mmol) in solvent (10 mL) at room temperature and reflux for 16 h. After adding Et₂O (20 mL) to the mixtures at room temperature, insoluble materials were removed by filtration through silicagel pad with suction. The filtrate was concentrated in vaccuo, and the residue was purified by silica gel column chromatography with hexane/AcOEt (5/1) to give **3a** as white solids.

General procedure C for Scheme 2:

Cesium carbonate (652 mg, 2 mmol) was added to a mixture of indole (1 mmol), 2-halobenzamide (1.5 mmol), CuBr (14.4 mg, 0.1 mmol) in DMSO (10 mL) at room temperature and reflux under air. After adding Et₂O (20 mL) to the mixtures at room temperature, insoluble materials were removed by filtration through silicagel pad with suction. The filtrate was concentrated in vaccuo, and the residue was purified by silica gel column chromatography with hexane/AcOEt (5/1) to give 3.

Methyl 5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3a).

Following the general procedure C, **3a** (214 mg, 73%) was obtained as white solids. 214 mg, 73%. White solids. Mp: 204-207 °C (EtOH). IR (CHCl₃): 3404, 1705, 1612, 1597 cm⁻¹. ¹H-NMR (CDCl₃) δ : 4.01 (s, 3H), 7.34 (td, J = 1.8, 7.7 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.48 (t, J = 7.5Hz, 1H), 7.87 (td, J = 1.2, 7.6 Hz, 1H), 8.10 (d, J = 8.6 Hz, 1H), 8.12 (d, J = 8.0 Hz, 1H), 8.35 (d, J = 8.6 Hz, 1H), 8.43 (dd, J = 1.7, 8.0 Hz, 1H), 10.57 (br s, 1H). ¹³C-NMR (CDCl₃) δ : 51.5, 87.9, 113.1, 115.6, 117.7, 121.2, 122.7, 124.3, 125.2, 127.0, 130.0, 131.1, 135.3, 138.7, 142.3, 158.0, 166.2. HR-ESI-MS m/z: Calcd for C₁₇H₁₂N₂NaO₃ [(M+Na)⁺]: 315.0746. Found 315.0748.

2-(3-Methyl-1*H*-indol-1-yl)benzamide (4a).

Following the general procedure C, 4a (159 mg, 64%) was obtained as colorless oil. 159 mg, 64%. Colorless oil. IR (CHCl₃): 3400, 1672, 1603, 1584 cm⁻¹. ¹H-NMR (CDCl₃) δ: 2.38 (s, 3H), 5.30 (br s, 1H), 5.91 (br s, 1H), 7.00 (s, 1H), 7.16-7.19 (m, 3H), 7.36 (d, J = 8.1 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.61-7.63 (m, 1H), 8.01 (d, J = 7.5 Hz, 1H).¹³C-NMR

(CDCl₃) δ: 9.8, 110.3, 114.0, 119.4, 120.4, 123.1, 126.2, 128.2, 128.4, 129.5, 131.2, 131.9, 132.2, 136.9, 137.3, 168.4. HR-ESI-MS m/z: Calcd for C₁₆H₁₄N₂NaO [(M+Na)⁺]: 273.1004. Found 273.1002.

Indolo[1,2-*a*]quinazoline-5,7-dione (5).

Following the general procedure C, 5 (55 mg, 22%) was obtained as white solids. 55 mg, 22%. White solids. Mp: 256-258 °C (EtOH). IR (CHCl₃): 3442, 3236, 1728, 1694, 1599 cm⁻ ¹. ¹H-NMR (DMSO- d_6) δ : 7.45 (t, J = 7.5 Hz, 1H), 7.71 (dt, J = 4.0, 4.6 Hz, 1H), 7.83 (d, J = 8.1Hz, 1H), 7.85 (d, J = 7.5 Hz, 1H), 7.92 (d, J = 4.6 Hz, 2H), 8.29 (d, J = 7.5 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H). ¹³C-NMR (DMSO-*d*₆) δ: 117.6, 122.8, 123.9, 125.2, 127.5, 127.5, 130.3, 130.4, 135.6, 138.3, 145.5, 146.6,





147.1, 158.2, 182.9. HR-ESI-MS m/z: Calcd for C₁₅H₉N₂O₂ [(M+H)⁺]: 249.0664. Found 249.0663.

4. Synthesis of 3a-o, 4b:

Methyl 9-methoxy-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3b).

Following the general procedure C, **3b** (168 mg, 52%) was obtained as white solids. 168 mg, 52%. White solids. Mp: 196-198 °C (EtOH). IR (CHCl₃): 3368, 3300, 1681, 1602 cm⁻ ¹. ¹H-NMR (CDCl₃) δ : 3.89 (s, 3H), 3.98 (s, 3H), 6.86 (d, J = 9.2 Hz, 1H), 7.43 (t, J = 8.2 Hz, 1H), 7.52 (s, 1H), 7.82 (t, J = 7.5 Hz, 1H), 7.88 (dd, J = 3.5, 9.2 Hz, 1H), 8.18 (dd, J = 3.5, 8.1 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 10.41 (br s, 1H). ¹³C-NMR (CDCl₃) δ : 51.4, 55.7, 87.7, 104.0, 110.8, 113.8, 115.2, 117.4, 124.9, 125.5, 128.3, 129.9, 135.2, 138.4, 142.2, 156.9, 157.8, 165.9. HR-ESI-MS *m/z*: Calcd for C₁₈H₁₅N₂O₄ [(M+H)⁺]: 323.1032. Found 323.1030.

Methyl 9-chloro-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3c).

Following the general procedure C, 3c (259 mg, 79%) was obtained as white solids. 259 mg, 79%. White solids. Mp: 230-233 °C (EtOH). IR (CHCl₃): 3300, 1684, 1607 cm⁻¹. ¹H-NMR (CDCl₃) δ : 4.00 (s, 3H), 7.24-7.26 (m, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.86 (t, J = 8.6 Hz, 1H), 3c 7.95 (d, J = 8.6 Hz, 1H), 8.01 (s, 1H), 8.20 (d, J = 8.6 Hz, 1H), 8.41 (d, J = 7.5 Hz, 1H), 10.49 (br s, 1H). ¹³C-NMR (CDCl₃) δ: 51.7, 87.5, 113.9, 115.4, 117.7, 120.8, 122.7, 125.5, 128.3, 129.3, 130.1, 135.4, 138.2, 142.7, 157.7, 165.6 (one sp² signal was not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₁₇H₁₁ClN₂O₃ [(M+H)⁺]: 327.0536, 329.0507. Found 327.0535, 329.0512.

Methyl 9-bromo-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3d).

Following the general procedure C, 3d (304 mg, 82%) was obtained as white solids. 304 mg, 82%. White solids. Mp: 239-242 °C (EtOH). IR (CHCl₃): 3300, 1674, 1608 cm⁻¹. ¹H-CO₂Me NMR (CDCl₃) δ : 4.00 (s, 3H), 7.41 (dd, J = 1.7, 8.6 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.87 (t, J = 1.7, 8.6 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.87 (t, J = 1.7, 8.6 Hz, 1H), 7.50 (t, J = 1.5 Hz, 1H), 7.87 (t, J = 1.7, 8.6 Hz, 1H), 7.50 (t, J = 1.5 Hz, 1H), 7.87 (t, J = 1.5 Hz, 1H), 7.8 8.1 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 8.20 (s, 1H), 8.22 (d, J = 8.6 Hz, 1H), 8.42 (d, J = 7.4 Hz, 1H), 10.49 (br s, 1H). ¹³C-NMR (CDCl₃) δ: 51.7, 87.4, 114.3, 115.4, 117.7, 117.9, 123.8, 125.4, 3d 125.5, 128.7, 129.7, 130.1, 135.4, 138.2, 142.7, 157.7, 165.6 (one sp² signal was not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₁₇H₁₁BrN₂NaO₃ [(M+Na)⁺]: 392.9851, 394.9830. Found 392.9849, 394.9833.

Methyl 6-methyl-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3f).

Following the general procedure C, **3f** (260 mg, 85%) was obtained as white solids. 260 mg, 85%. White solids. Mp: 192-193 °C (EtOH). IR (CHCl₃): 1697, 1678, 1604 cm⁻¹. ¹H-NMR $(CDCl_3)$ δ : 3.77 (s, 3H), 4.01 (s, 3H), 7.35-7.40 (m, 2H), 7.44 (t, J = 7.5 Hz, 1H), 7.83 (dt, J = 1.8, 7.5 Hz, 1H), 8.10-8.14 (m, 2H), 8.37 (d, J = 8.6 Hz, 1H), 8.43 (dd, J = 1.2, 7.5 Hz, 1H). ¹³C-NMR (CDCl₃) δ: 36.0, 51.7, 92.8, 113.0, 115.3, 116.9, 121.1, 122.9, 123.8, 124.8, 128.3, 130.0, 130.5, 3f 134.8, 138.0, 141.4, 159.9, 164.7. HR-ESI-MS *m/z*: Calcd for C₁₈H₁₄N₂NaO₃ [(M+Na)⁺]: 329.0902. Found 329.0902.









Methyl 9-methoxy-6-methyl-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3g).

Following the general procedure C, 3g (239 mg, 71%) was obtained as white solids.

239 mg, 71%. White solids. Mp: 206-208 °C (EtOH). IR (CHCl₃): 1684, 1603 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.74 (s, 3H), 3.92 (s, 3H), 3.99 (s, 3H), 6.94 (dd, *J* = 2.9, 9.2 Hz, 1H), 7.41 (t, *J* = 7.5 Hz, 1H), 7.59 (d, *J* = 2.3 Hz, 1H), 7.79 (dt, *J* = 1.2, 6.9 Hz, 1H), 7.98 (d, *J* = 9.2 Hz, 1H), 8.26 (d, *J* = 8.6 Hz, 1H), 8.41 (dd, *J* = 1.2, 8.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 36.3, 51.7, 55.8, 92.6, 103.9, 111.4, 113.8, 115.0, 116.7, 124.6, 125.2, 129.6, 129.9, 134.8, 137.9, 141.8, 156.5, 159.9, 164.7. HR-ESI-MS *m/z*: Calcd for C₁₉H₁₇N₂O₄ [(M+H)⁺]: 337.1188. Found 337.1181.

Methyl 9-chloro-6-methyl-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3h).

Following the general procedure C, **3h** (299 mg, 88%) was obtained as white solids.

299 mg, 88%. White solids. Mp: 196-198 °C (EtOH). IR (CHCl₃): 1699, 1681, 1602 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.75 (s, 3H), 4.01 (s, 3H), 7.29 (dd, J = 1.2, 8.6 Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.83 (dt, J = 1.2, 7.4 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 8.07 (d, J = 1.7 Hz, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.43 (d, J = 8.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 36.1, 51.9, 92.4, 113.9, 115.2, 117.0,

120.8, 122.9, 125.2, 128.8, 129.6, 130.1, 135.0, 137.6, 142.3, 159.8, 164.2 (one sp² signal was not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₁₈H₁₃ClN₂NaO₃ [(M+Na) ⁺]: 363.0512, 365.0483. Found 363.0512, 365.0484.

Methyl 9-bromo-6-methyl-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3i).

Following the general procedure C, **3i** (351 mg, 91%) was obtained as white solids. 351 mg, 91%. White solids. Mp: 210-212 °C (EtOH). IR (CHCl₃): 1701, 1682 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.75 (s, 3H), 4.01 (s, 3H), 7.44 (dd, J = 1.7, 8.6 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.83 (dt, J = 1.7, 7.7 Hz, 1H), 7.97 (d, J = 8.6 Hz, 1H), 8.22 (d, J = 1.7 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.43 (dd, J = 1.2, 8.1 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 36.1, 51.9, 92.3, 114.2, 115.2, 117.0, 117.4, 123.8, 125.2, 125.7, 129.2, 130.0, 130.2, 135.0, 137.6, 142.1, 159.8, 164.2. HR-ESI-MS *m/z*: Calcd for C₁₈H₁₃BrN₂NaO₃ [(M+Na)⁺]: 407.0007, 408.9987. Found 407.0005, 408.9990.

Methyl 1-(2-(tert-butylcarbamoyl)phenyl)-1H-indole-3-carboxylate (4b).

Following the general procedure C, **4b** (190 mg, 54%) was obtained as colorless viscous oil. 1.90 mg, 54%. Colorless viscous oil. IR (CHCl₃): 3428, 3323, 1705, 1664 cm⁻¹. ¹H-NMR (CDCl₃) δ : 0.84 (s, 9H), 3.92 (s, 3H), 4.88 (br s, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.26 (td, J = 1.2, 8.6 Hz, 1H), 7.32 (td, J = 1.2, 8.1 Hz, 1H), 7.41 (dd, J = 1.7, 8.0 Hz, 1H), 7.55-7.62 (m, 2H), 7.88 (dd, J = 2.3, 7.5 Hz, 1H), 7.93 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 27.9, 51.3, 51.6, 109.7, 110.8, 122.0, 123.0, 124.2, 126.4, 127.9, 129.6, 130.7,

131.4, 134.5, 134.6, 135.5, 137.9, 164.9, 165.2 (two sp³ signals were not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₂₁H₂₂N₂NaO₃ [(M+Na)⁺]: 373.1528. Found 373.1529.





CO₂Me Me

> -Me Me

О-Ме



Methyl 6-benzyl-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3k).

Following the general procedure C, 3k (355 mg, 93%) was obtained as white solids. 355 mg, 93%. White solids. Mp: 162-164 °C (EtOH). IR (CHCl₃): 1693, 1682, 1603 cm⁻¹. ¹H-CO₂Me NMR (CDCl₃) δ: 3.85 (s, 3H), 5.94 (s, 2H), 7.11 (d, J = 6.9 Hz, 2H), 7.15-7.21 (m, 3H), 7.30-7.33 (m, 2H), 7.44 (t, J = 7.5 Hz, 1H), 7.82 (dt, J = 1.2, 7.5 Hz, 1H), 7.90-7.92 (m, 1H), 8.09-8.11 (m, 1H), 8.35 (d, J = 8.6 Hz, 1H), 8.46 (dd, J = 1.7, 8.0 Hz, 1H). ¹³C-NMR 3k (CDCl₃) δ: 47.4, 51.9, 94.2, 113.0, 115.5, 116.9, 121.2, 122.8, 123.6, 124.8, 127.1, 127.4, 128.2, 128.5, 130.4, 134.9, 136.0, 138.1, 138.8. HR-ESI-MS *m/z*: Calcd for C₂₄H₁₈N₂NaO₃ [(M+Na) ⁺]: 405.1215. Found 405.1215.

Methyl 5-oxo-6-phenyl-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3).

Following the general procedure C, 31 (317 mg, 86%) was obtained as white solids. 317 mg, 86%. White solids. Mp: 212-215 °C (EtOH). IR (CHCl₃): 1686, 1603 cm⁻¹. ¹H-NMR $(CDCl_3) \delta$: 3.22 (s, 3H), 7.34-7.38 (m, 2H), 7.41-7.44 (m, 2H), 7.47-7.53 (m, 4H), 7.83 (dt, J =1.2, 7.5 Hz, 1H), 7.93-7.94 (m, 1H), 8.13-8.14 (m, 1H), 8.37 (d, J = 8.6 Hz, 1H), 8.42 (dd, J = 1.2, 8.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ: 51.5, 93.8, 113.0, 115.4, 117.1, 120.5, 123.0, 123.8, 124.7, 127.8, 128.4, 128.5, 129.2, 130.4, 130.5, 135.2, 138.5, 138.6, 139.0, 159.1, 163.9 (two sp² signals were not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₂₃H₁₆N₂NaO₃ [(M+Na)⁺]: 391.1059. Found 391.1060.

Methyl 6-benzyl-3-methyl-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3m).

Following the general procedure C, 3m (319 mg, 80%) was obtained as white solids. 319 mg, 80%. White solids. Mp: 158-160 °C (EtOH). IR (CHCl₃): 1692, 1674 cm⁻¹. ¹H-NMR $(CDCl_3)$ δ : 2.46 (s, 3H), 3.86 (s, 3H), 5.94 (s, 2H), 7.10 (d, J = 6.9 Hz, 2H), 7.13-7.21 (m, 3H), 7.27-7.29 (m, 2H), 7.55 (d, J = 8.6 Hz, 1H), 7.88-7.90 (m, 1H), 8.01 (d, J = 4.0 Hz, 1H), 8.15 (d, J = 7.5 Hz, 1H), 8.22 (s, 1H). ¹³C-NMR (CDCl₃) δ : 20.9, 47.4, 51.9, 93.8, 112.9, 115.4, 116.6,

121.1, 122.7, 123.5, 127.1, 127.4, 128.1, 128.5, 130.1, 130.2, 134.8, 135.8, 136.1, 138.7, 160.1, 165.2 (three sp² signals were not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₂₅H₂₀N₂NaO₃ [(M+Na)⁺]: 419.1372. Found 419.1372.

Methyl 6-benzyl-3-chloro-5-oxo-5,6-dihydroindolo[1,2-a]quinazoline-7-carboxylate (3n).

Following the general procedure C, **3n** (300 mg, 72%) was obtained as white solids. 300 mg, 72%. White solids. Mp: 204-206 °C (EtOH). IR (CHCl₃): 1697, 1678 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.85 (s, 3H), 5.91 (s, 2H), 7.09 (d, J = 7.4 Hz, 2H), 7.14-7.21 (m, 3H),









7.28-7.32 (m, 2H), 7.72 (dd, J = 2.3, 8.6 Hz, 1H), 7.88-7.89 (m, 1H), 7.98 (d, J = 3.5 Hz, 1H), 8.24 (dd, J = 4.0, 9.2 Hz, 1H), 8.39 (d, J = 2.0 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 47.5, 52.0, 94.6, 112.7, 116.9, 118.2, 121.3, 123.1, 123.9, 127.1, 127.5, 128.1, 128.6, 129.8, 130.1, 130.4, 134.9, 135.7, 136.5, 138.2, 158.9, 164.9 (two sp² signals were not observed because of overlapping). HR-ESI-MS *m/z*: Calcd for C₂₄H₁₇ClN₂NaO₃ [(M+Na) ⁺]: 439.0825, 441.0796. Found 439.0825, 441.0798.

Methyl 5-oxo-5,6-dihydropyrido[3',2':5,6]pyrimido[1,2-*a*]indole-7-carboxylate (30).

Following the general procedure C, **30** (155 mg, 53%) was obtained as white solids. 155 mg, 53%. White solids. Mp: 222-224 °C (EtOH). IR (CHCl₃): 3304, 1689, 1628 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.99 (s, 3H), 7.29 (dt, *J* = 1.2, 8.6 Hz, 1H), 7.34 (dt, *J* = 1.1, 7.5 Hz, 1H), 7.41 (dd, *J* = 4.6, 7.5 Hz, 1H), 7.96 (d, *J* = 7.5 Hz, 1H), 8.60 (dd, *J* = 2.3, 8.0 Hz, 1H), 8.81 (dd, *J* = 2.3, 5.2 Hz, 1H), 8.92 (d, *J* = 8.0 Hz, 1H), 10.38 (br s, 1H). ¹³C-NMR (CDCl₃) δ : 51.6, 89.1, 112.8, 116.3, 120.3, 120.8, 123.2, 124.8, 126.0, 130.8, 138.2, 141.2, 149.9, 153.9, 158.1, 166.1. HR-ESI-MS *m/z*: Calcd for C₁₆H₁₁N₃NaO₃ [(M+Na)⁺]: 316.0698. Found 316.0700.



5. Synthesis of 3p:

Methyl 6-benzyl-3-bromo-5-oxo-5,6-dihydroindolo[1,2-*a*]quinazoline-7-carboxylate (3p).

Cesium carbonate (652 mg, 2 mmol) was added to a mixture of methyl indole-3-carboxylate (175 mg, 1 mmol), 2,5dibromobenzamide (554 mg, 1.5 mmol), CuBr (14.4 mg, 0.1 mmol) in DMSO (10 mL) at room temperature and reflux for 48 h under air. After adding Et₂O (20 mL) to the mixtures at room temperature, insoluble materials were removed by filtration through silicagel pad with suction. The filtrate was concentrated in vaccuo, and the residue was purified by silica gel column chromatography with hexane/AcOEt (5/1) to give **3p** (315 mg, 68%) as white solids.

315 mg, 68%. White solids. Mp: 215-217 °C (EtOH). IR (CHCl₃): 1697, 1676 cm⁻¹. ¹H-NMR (CDCl₃) δ : 3.85 (s, 3H), 5.91 (s, 2H), 7.09 (d, *J* = 6.9 Hz, 2H), 7.14-7.21 (m, 3H), 7.29-7.34 (m, 2H), 7.88-7.91 (m, 2H), 8.00-8.02 (m, 1H), 8.22 (d, *J* = 8.6 Hz, 1H), 8.57 (d, *J* = 2.3 Hz, 1H). ¹³C-NMR (CDCl₃) δ : 47.5, 52.0, 94.7, 112.8, 117.2, 117.8, 118.4, 121.4, 123.2, 123.9, 127.1, 127.5, 128.2, 128.6, 130.2, 132.9, 135.7, 136.9, 137.7, 138.3, 158.9, 164.9 (two sp²)



signals were not observed because of overlapping). HR-ESI-MS m/z: Calcd for C₂₄H₁₇BrN₂NaO₃ [(M+Na) ⁺]: 483.0320, 485.0300. Found 483.0297, 485.0305.

6. References

- (1) Linton, E. C.; Kozlowski, M. C. J. Am. Chem. Soc. 2008, 130, 16162.
- (2) Abe, T.; Yamada, K. Org. Lett. 2016, 18, 6504.



































































